Ignite Creation Date:
2024-05-05 @ 4:48 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00315757
Status:
COMPLETED
Last Update Posted:
2013-08-08
First Post:
2006-04-17
Brief Title:
Study of Mapatumumab in Combination With Bortezomib Velcade and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Sponsor:
Human Genome Sciences Inc
Organization:
Human Genome Sciences Inc
Study Overview
Official Title:
A Phase 2 Multi-Center Open-Label Randomized Study of Mapatumumab TRM-1 HGS1012 a Fully Human Monoclonal Antibody to TRAIL-R1 in Combination With Bortezomib Velcade and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
COMPLETED
Status Verified Date:
2013-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the efficacy disease response and safety of mapatumumab in combination with bortezomib and bortezomib alone in subjects with relapsed or refractory multiple myeloma MM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None